Abstract
ObjectiveThe purpose of this study was to develop a model using dose volume histogram (DVH) and dosiomic features to predict the risk of radiation pneumonitis (RP) in the treatment of esophageal cancer with radiation therapy and to compare the performance of DVH and dosiomic features after adjustment for the effect of fractionation by correcting the dose to the equivalent dose in 2 Gy (EQD2).Materials and methodsDVH features and dosiomic features were extracted from the 3D dose distribution of 101 esophageal cancer patients. The features were extracted with and without correction to EQD2. A predictive model was trained to predict RP grade ≥ 1 by logistic regression with L1 norm regularization. The models were then evaluated by the areas under the receiver operating characteristic curves (AUCs).ResultThe AUCs of both DVH-based models with and without correction of the dose to EQD2 were 0.66 and 0.66, respectively. Both dosiomic-based models with correction of the dose to EQD2 (AUC = 0.70) and without correction of the dose to EQD2 (AUC = 0.71) showed significant improvement in performance when compared to both DVH-based models. There were no significant differences in the performance of the model by correcting the dose to EQD2.ConclusionDosiomic features can improve the performance of the predictive model for RP compared with that obtained with the DVH-based model.
Highlights
Esophageal cancer is a thoracic cancer for which radiotherapy (RT) is an effective treatment [1]
Dosiomic features can improve the performance of the predictive model for radiation pneumonitis (RP) compared with that obtained with the dose volume histogram (DVH)-based model
The data showed that there was no significant difference observed in the performance when correcting dose distribution to equivalent dose in 2 Gy (EQD2) in either model (DVH model and DVHEQD2 model (p value = 0.56), dosiomic features (DO) model and Dosiomic calculate from dose distribution with EQD2 (DOEQD2) model (p value = 0.73))
Summary
Esophageal cancer is a thoracic cancer for which radiotherapy (RT) is an effective treatment [1]. Radiation pneumonitis (RP) is one of the side effects of thoracic radiation therapy, occurring in patients whose lungs have been irradiated during treatments for malignancy. Several researchers have reported improved toxicity prediction performance after radiation therapy by dosiomics [5,6,7], including for RP [8,9,10]. Studies on dosiomics as features for the prediction of RP were performed in lung cancer patients. Due to differences in dose distribution to the lung and other confounding factors in lung cancer that are associated with the risk of RP, such as tumor location [11] and changes in gross tumor volume (GTV) during treatment, a model developed for patients lung cancer may not be applicable to esophageal cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
